CO2024001383A2 - Formulaciones de anticuerpos - Google Patents
Formulaciones de anticuerposInfo
- Publication number
- CO2024001383A2 CO2024001383A2 CONC2024/0001383A CO2024001383A CO2024001383A2 CO 2024001383 A2 CO2024001383 A2 CO 2024001383A2 CO 2024001383 A CO2024001383 A CO 2024001383A CO 2024001383 A2 CO2024001383 A2 CO 2024001383A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibody formulations
- composition comprises
- example embodiments
- liquid composition
- liquid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163232299P | 2021-08-12 | 2021-08-12 | |
| US202263316604P | 2022-03-04 | 2022-03-04 | |
| PCT/US2022/040056 WO2023018870A1 (en) | 2021-08-12 | 2022-08-11 | Antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024001383A2 true CO2024001383A2 (es) | 2024-03-07 |
Family
ID=83151728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0001383A CO2024001383A2 (es) | 2021-08-12 | 2024-02-08 | Formulaciones de anticuerpos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240343795A1 (https=) |
| EP (1) | EP4384217A1 (https=) |
| JP (1) | JP2024532736A (https=) |
| KR (1) | KR20240046881A (https=) |
| AU (1) | AU2022325870A1 (https=) |
| CA (1) | CA3228269A1 (https=) |
| CL (1) | CL2024000401A1 (https=) |
| CO (1) | CO2024001383A2 (https=) |
| CR (1) | CR20240130A (https=) |
| IL (1) | IL310275A (https=) |
| JO (1) | JOP20240024A1 (https=) |
| MX (1) | MX2024001934A (https=) |
| PE (1) | PE20240650A1 (https=) |
| TW (1) | TW202319398A (https=) |
| UY (1) | UY39896A (https=) |
| WO (1) | WO2023018870A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026062214A1 (en) * | 2024-09-19 | 2026-03-26 | Sanofi | Formulations comprising lunsekimig |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| EP2963057A1 (en) | 2014-07-02 | 2016-01-06 | Calypso Biotech SA | Antibodies to IL-15 |
| WO2017217985A1 (en) | 2016-06-15 | 2017-12-21 | Amgen Inc. | Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease |
| WO2018119142A1 (en) * | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| MA48464A (fr) * | 2017-04-28 | 2020-03-04 | Amgen Inc | Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques |
| EA201992570A1 (ru) | 2017-04-28 | 2020-03-20 | Эмджен Инк. | Составы на основе человеческих антител к rankl, а также способы их применения |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| WO2021079337A1 (en) * | 2019-10-23 | 2021-04-29 | Cadila Healthcare Limited | Pharmaceutical formulation of anti-her2 antibody and preparation thereof |
-
2022
- 2022-08-11 AU AU2022325870A patent/AU2022325870A1/en active Pending
- 2022-08-11 MX MX2024001934A patent/MX2024001934A/es unknown
- 2022-08-11 KR KR1020247007623A patent/KR20240046881A/ko active Pending
- 2022-08-11 WO PCT/US2022/040056 patent/WO2023018870A1/en not_active Ceased
- 2022-08-11 EP EP22762210.7A patent/EP4384217A1/en active Pending
- 2022-08-11 PE PE2024000233A patent/PE20240650A1/es unknown
- 2022-08-11 CR CR20240130A patent/CR20240130A/es unknown
- 2022-08-11 CA CA3228269A patent/CA3228269A1/en active Pending
- 2022-08-11 US US18/682,531 patent/US20240343795A1/en active Pending
- 2022-08-11 JP JP2024507886A patent/JP2024532736A/ja active Pending
- 2022-08-11 IL IL310275A patent/IL310275A/en unknown
- 2022-08-11 UY UY0001039896A patent/UY39896A/es unknown
- 2022-08-11 TW TW111130262A patent/TW202319398A/zh unknown
-
2024
- 2024-02-08 CO CONC2024/0001383A patent/CO2024001383A2/es unknown
- 2024-02-08 JO JOJO/P/2024/0024A patent/JOP20240024A1/ar unknown
- 2024-02-09 CL CL2024000401A patent/CL2024000401A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202319398A (zh) | 2023-05-16 |
| IL310275A (en) | 2024-03-01 |
| JP2024532736A (ja) | 2024-09-10 |
| JOP20240024A1 (ar) | 2024-02-08 |
| CL2024000401A1 (es) | 2024-06-21 |
| WO2023018870A1 (en) | 2023-02-16 |
| US20240343795A1 (en) | 2024-10-17 |
| AU2022325870A1 (en) | 2024-02-08 |
| PE20240650A1 (es) | 2024-04-04 |
| MX2024001934A (es) | 2024-03-04 |
| CA3228269A1 (en) | 2023-02-16 |
| CR20240130A (es) | 2024-04-12 |
| KR20240046881A (ko) | 2024-04-11 |
| EP4384217A1 (en) | 2024-06-19 |
| UY39896A (es) | 2023-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2569409T3 (es) | Composiciones de anticuerpo anti-CTLA-4 | |
| AR111773A1 (es) | Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración | |
| CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
| ECSP099642A (es) | Formulaciones estables de anticuerpo | |
| BR122019027966B8 (pt) | conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos | |
| ECSP077261A (es) | Composición de anticuerpo her2 | |
| HRP20120903T1 (hr) | Tekuä†a formulacija koja sadrži visoku koncentraciju protutijela | |
| EA201200475A1 (ru) | Высококонцентрированные фармацевтические композиции, содержащие антитело к cd20 | |
| ECSP088528A (es) | Formulación de profármacos para el vhc | |
| MX2024000901A (es) | Composiciones y metodos para la degradacion selectiva de proteinas dise?adas por ingenieria. | |
| CR20210318A (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| CO2024001383A2 (es) | Formulaciones de anticuerpos | |
| AU2019339740A8 (en) | CSF-1R antibody formulation | |
| AR117407A1 (es) | Formulaciones acuosas estables de anticuerpos anti-tau | |
| UY39878A (es) | Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma | |
| AR129796A1 (es) | Composiciones de tirzepatida y uso | |
| BR112019025591A2 (pt) | Composição farmacêutica compreendendo conjugado de fármaco-anticorpo c-met e uso do mesmo | |
| CL2023000004A1 (es) | Formulación en concentración alta de proteínas de unión a antígeno del factor xii | |
| BR112022022620A2 (pt) | Formulações de anticorpos anti-il-33 | |
| CO2025000182A2 (es) | Formulación de anticuerpos anti-c1s del complemento | |
| CO2024013582A2 (es) | Formulación liofilizada que comprende una proteína de fusión que incluye α-galactosidasa a | |
| CL2024003444A1 (es) | Formulación farmacéutica líquida estable que comprende un anticuerpo biespecífico anti-cd20/cd3 humano. | |
| MX2025014226A (es) | Composiciones de proteinas conjugadas y no conjugadas | |
| CO2023014918A2 (es) | Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-muc16 x anti-cd3 | |
| AR126769A1 (es) | Formulaciones de anticuerpos |